UBS Group
CCEL icon

UBS Group’s Cryo-Cell International CCEL Stock Holding History

UBS Group’s Portfolio CCEL Stock Details CCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Sell
316
-356
-53% -$1.27K ﹤0.01% 9658
2026
Q1 		$2.39K Buy
672
+459
+215% +$1.53K ﹤0.01% 9288
2025
Q4 		$733 Buy
213
+82
+63% +$340 ﹤0.01% 9833
2025
Q3 		$608 Buy
131
+31
+31% +$147 ﹤0.01% 9603
2025
Q2 		$519 Sell
100
-1,396
-93% -$7.36K ﹤0.01% 9806
2025
Q1 		$9.53K Sell
1,496
-1,652
-52% -$12K ﹤0.01% 8685
2024
Q4 		$23.3K Buy
3,148
+2,899
+1,164% +$21.9K ﹤0.01% 7778
2024
Q3 		$1.59K Buy
+249
New +$1.72K ﹤0.01% 8600
2024
Q1 		– Sell
-741
Closed -$4.26K – 9376
2023
Q4 		$4.26K Buy
+741
New +$3.84K ﹤0.01% 7887
2023
Q2 		– Sell
-177
Closed -$535 – 8975
2023
Q1 		$535 Sell
177
-1,547
-90% -$5.97K ﹤0.01% 8983
2022
Q4 		$7.29K Buy
1,724
+1,587
+1,158% +$7.6K ﹤0.01% 8914
2022
Q3 		$1K Sell
137
-132
-49% -$814 ﹤0.01% 9933
2022
Q2 		$2K Sell
269
-1,160
-81% -$7.42K ﹤0.01% 9516
2022
Q1 		$11K Buy
1,429
+1,425
+35,625% +$13.1K ﹤0.01% 8286
2021
Q4 		$0 Sell
4
-148
-97% -$1.84K ﹤0.01% 10277
2021
Q3 		$2K Buy
+152
New +$1.87K ﹤0.01% 8932

Other funds holding CCEL

SA
SFI Advisors Montclair, New Jersey $116M AUM 37.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's CCEL Position: Q2 2026 in Review

UBS Group reduced its Cryo-Cell International (CCEL) stake by 53% in Q2 2026, selling an estimated $1.27K and leaving 316 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #9658.

UBS Group first reported a position in CCEL in Q3 2021 and has held it in 16 quarters since. The position peaked at $23.3K in Q4 2024. 12 funds tracked by Wall St. Rank hold CCEL as of Q2 2026.

  • UBS Group held 316 shares of Cryo-Cell International worth $1.01K as of Q2 2026.
  • UBS Group sold 356 Cryo-Cell International shares in Q2 2026, an estimated $1.27K.
  • Cryo-Cell International made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9658 holding.
  • UBS Group first reported a position in Cryo-Cell International in Q3 2021 and has held it in 16 quarters since.
  • UBS Group's Cryo-Cell International position peaked at $23.3K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held Cryo-Cell International as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.